GlassScriptPhysician profile
Barbara Muir
NPI 1104811181
$4,094.30
in general payments reported to CMS, 2019-2025
26 companies · $824 in 2025
The $824 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $278 · 2023: $1,577 · 2024: $1,415 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,803 · Education: $13.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,802.59 |
| Education | $13.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $594.48 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $505.00 | 2022-2025 | Farxiga, Fasenra, Breztri |
| Abbvie INC. | $459.19 | 2022-2025 | |
| Glaxosmithkline, LLC. | $434.11 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $334.14 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $244.21 | 2023-2025 | |
| Exact Sciences Corporation | $225.32 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $151.46 | 2023-2025 | Repatha, Prolia, Evenity |
| Merck Sharp & Dohme LLC | $124.86 | 2023-2025 | Gardasil 9, Verquvo, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.97 | 2024-2025 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $92.02 | 2024-2025 | Gemtesa |
| Abbott Laboratories | $87.06 | 2023-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.12 | 2023-2025 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Biogen, INC. | $76.60 | 2025 | Skyclarys |
| Axsome Therapeutics, INC. | $76.45 | 2022-2023 | Auvelity |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $74.25 | 2023 | Myrisk |
| Takeda Pharmaceuticals U.S.A., INC. | $71.59 | 2022-2023 | Trintellix |
| Inspire Medical Systems, INC. | $68.10 | 2024-2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $57.66 | 2023-2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $52.11 | 2022 | |
| Lundbeck LLC | $32.39 | 2023 | Rexulti |
| Astellas Pharma US INC | $32.39 | 2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $30.35 | 2023 | |
| Verona Pharma, INC. | $29.59 | 2025 | Ohtuvayre |
| Shield Therapeutics INC | $21.75 | 2023 | Accrufer |
| Corcept Therapeutics | $20.13 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Muir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.